DexCom, Inc. $DXCM Shares Purchased by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 75.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 99,189 shares of the medical device company’s stock after buying an additional 42,652 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in DexCom were worth $8,658,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Golden State Wealth Management LLC boosted its holdings in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new stake in DexCom in the 1st quarter valued at about $27,000. Anderson Financial Strategies LLC purchased a new position in shares of DexCom in the 1st quarter valued at about $37,000. Private Trust Co. NA boosted its stake in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after buying an additional 335 shares during the period. Finally, Horizon Financial Services LLC acquired a new position in shares of DexCom during the first quarter worth about $56,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $70.33 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a market capitalization of $27.58 billion, a PE ratio of 48.84, a P/E/G ratio of 1.48 and a beta of 1.47. The company has a fifty day moving average of $72.37 and a two-hundred day moving average of $77.90.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the firm earned $0.43 earnings per share. The business’s revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on DXCM. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Stifel Nicolaus initiated coverage on shares of DexCom in a research note on Tuesday, October 21st. They set a “buy” rating and a $85.00 target price for the company. Argus assumed coverage on DexCom in a report on Thursday, August 21st. They issued a “buy” rating and a $100.00 target price on the stock. Cowen reaffirmed a “buy” rating on shares of DexCom in a report on Friday. Finally, Piper Sandler set a $100.00 price objective on DexCom and gave the company an “overweight” rating in a report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $97.19.

Insider Transactions at DexCom

In other news, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the transaction, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. The trade was a 2.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock worth $564,733 in the last three months. Corporate insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.